Abstract
Background: Several phase 3 clinical trials have demonstrated the benefit of CDK4/6 inhibitors (iCDK4/6) associated with endocrine therapy on survival outcomes, with a manageable toxicity profile. Despite the high prevalence of breast cancer patients over 65 years, this population is usually underrepresented in trials, which leads to an extrapolation of data from younger and healthier patients. However, the geriatric population is heterogeneous in terms of comorbidities and performance status. The aim of this study is to evaluate the clinical benefit (CB) and toxicities of ribociclib (R) and palbociclib (P) in the elderly population of our Center.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
